Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | STAT1 | P42224 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coumarin SCHEMBL9330710 | 0.87 | ERAP1 (0.54) | ERAP1KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL7121658 | 0.87 | CA1 (0.56) | ERAP1KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL19484976 | 0.86 | CYP1B1 (0.60) | ERAP1KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL28721778 | 0.84 | ERAP1 (0.51) | ERAP1KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL7117054 | 0.84 | MAOB (0.72) | ERAP1KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL14307644 | 0.83 | ERAP1 (0.61) | ERAP1KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL1800595 | 0.83 | CA1 (0.56) | ERAP1KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL13769238 | 0.81 | MAOB (0.53) | ERAP1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL3400662 | 0.81 | ERAP1 (0.58) | ERAP1KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL5425943 | 0.81 | ERAP1 (0.79) | ERAP1KDM4EALDH1A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127092-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2015-09-08 | — | — | US | claimed |
| US-20140187725-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2014-07-03 | — | — | US | claimed |
| EP-1931345-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Medical and Research Center (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007024741-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2007-03-01 | — | — | WO | claimed |
| US-20060058245-A1 | Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2006-03-16 | — | — | US | claimed |
| EP-1562563-A4 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NAT JEWISH MED & RES CENTER (US) | 2005-12-28 | — | — | EP | claimed |
| EP-1562563-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Medical and Research Center (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004042020-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2004-05-21 | — | — | WO | claimed |
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-05-06 | — | — | US | claimed |
| CN-114349729-B | Coumarin derivative and preparation method and application thereof | 包头稀土研究院 | 2023-07-18 | — | — | CN | disclosed |
| CN-114349729-A | Coumarin derivative and preparation method and application thereof | 包头稀土研究院 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021070131-A1 | COMBINATION OF PHOTOINITIATORS AND USES THEREOF | IGM RESINS ITALIA S.R.L. (IT) | 2021-04-15 | — | — | WO | disclosed |
| CN-107973768-B | Method for synthesizing coumarin compound in one step | 江苏欣诺科催化剂有限公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-108409748-A | A kind of cumarin simultaneously [4,3-d] pyrazolo [3,4-b] pyridine derivate and its synthetic method | 苏州大学 | 2018-08-17 | — | — | CN | disclosed |
| EP-1309333-A2 | PLANT-DERIVED AND SYNTHETIC PHENOLIC COMPOUNDS AND PLANT EXTRACTS, EFFECTIVE IN THE TREATMENT AND PREVENTION OF CHLAMYDIAL INFECTIONS | Control-Ox OY (FI) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014464-A2 | PLANT-DERIVED AND SYNTHETIC PHENOLIC COMPOUNDS AND PLANT EXTRACTS, EFFECTIVE IN THE TREATMENT AND PREVENTION OF CHLAMYDIAL INFECTIONS | CONTROL-OX OY (FI) | 2002-02-21 | — | — | WO | disclosed |
| US-6255497-B1 | DAIDZIN DERIVATIVES AS ENZYME INHIBITORS OF ALDEHYDE DEHYDROGENASE; USEFUL IN TREATING ALCOHOLISM | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. | 2001-07-03 | — | — | US | disclosed |
| US-5886028-A | REDUCING ALCOHOL CONSUMPTION BY ADMINISTERING AN ENZYME INHIBITOR | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5624910-A | INHIBITING ALDEHYDE DEHYRDOGENASE ACTIVITY USING DAIDZIN | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1997-04-29 | — | — | US | disclosed |
| US-5204369-A | METHOD FOR THE INHIBITION OF ALDH-I USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY (US) | 1993-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | ABCC1, CFTR, ABCC2 | ERAP1 570/4885KDM4E 4861/4885ALDH1A1 401/4885 |
| US-20060058245-A1 | Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease | ABCC2, CFTR, ABCC1 | ERAP1 1455/4885KDM4E 4810/4885ALDH1A1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.